<?xml version="1.0" encoding="UTF-8"?>
<p id="p0170">Presently, treatment of COVID-19 is only supportive, and prevention is the only way to reduce the community transmission. Convalescent sera from COVID-19 positive patients has been approved by FDA in severe and critical patients only [
 <xref rid="bib27" ref-type="bibr">27</xref>]. Although no anti-viral therapy or other drugs till the time of writing is proven to work substantially against the COVID-19 in humans, few small-scale studies have claimed some benefit with chloroquine and hydroxychloroquine in less severely ill patients. Other drugs which are also being tried include Lopinavir/Ritonavir, Remdesivir, Favipiravir, Oseltamivir, Ribavirin, Interferon beta, Tocilizumab and Abidol [
 <xref rid="bib32" ref-type="bibr">32</xref>]. Multiple RCTs are currently undergoing with these agents and results are eagerly awaited.
</p>
